According to the Arizona Republic, “The chairman of Eli Lilly & Co. said the future of the pharmaceutical industry rests not with blockbuster drugs but with targeted therapies that work for smaller groups of people based on their biological makeup.” This is no huge surprise for those following biotech, but it is a significant departure for big pharma. In related news, Venture Beat says today that “Mohr Davidow Ventures, a Menlo Park, Calif. firm, has hired two biotech experts to help it make prudent investments in personalized healthcare companies.”
It’s a personalized medicine party.
Eli Lilly looks towards personalized medicine